The good news first: The Journal of Cachexia, Sarcopenia and Muscle (JCSM), now published in its 10th year, has nearly maintained last year's impact factor, even though it has decreased slightly, now reaching 10.754 as published by Thomson Scientific a few weeks ago. The impact factor is calculating from citations to the items in 2016 and 2017 divided by the number of items published in 2016 and 2017. It is important to understand that only the last full years count towards the impact factors, and this is why a journal that has been launched only 12 or 18 months ago can never have an impact factor even though some do calculate their 'unofficial impact factor', which should not be taken too seriously. In addition, it is important to note that the impact factor published in 2019 is the official 2018 impact factor, looked at and calculated using the citations and items published in the previous 2 years. So, at the time of this writing in July 2019, there is no 2019 impact factor, because this will only be published in 2020, usually in June. With regard to our own journal, we had total of 603 citations in 2016 and 838 in 2017. So that in total, 1441 citations were divided by 134 items published in these 2 years resulting in the calculated impact factor of 10.754.
1 Fortunately, this places JCSM as the number 9 ranked journal among all journals in 'Medicine: General and Internal' ( Table 1 ) and as the number 2 ranking journal among all nutrition journals, among which, however, JCSM is still not officially listed by Thomson Scientific. However, JCSM is listed in the category 'Gerontology', and it still reaches the top position there ( Table 2) .
As before, we would like to sincerely thank all authors, reviewers, and editorial board members for their great efforts to make JCSM such a high-quality and high-ranked journal, and we greatly appreciate and value the interest and support of all those who enjoy reading JCSM and citing the papers published there.
This year is unique for JCSM in several ways. The most important is the transfer of the two daughter journals of JCSM to Wiley as a publishing house. Indeed, JCSM appears to have sparked more scientific interest in the field of body wasting, cachexia, and sarcopenia, and thus, the number of submissions to the main journal remains on the increase. With a 73% rejection rate-knowing that we have to decline publication of many good papers simply for lack of space-we hope to be able to give some of these a home in our two daughter journals-JCSM Rapid Communications and JCSM Clinical Reports. JCSM Clinical Reports is online since December 2016 and JCSM Rapid Communications since January 2018. The first is dedicated to publishing clinical studies from the area of cachexia, wasting, and muscle disorders, and the second aims to publish both clinical and basic research papers with high relevance to the audience in this still niche area. We hope that the three journals will help in clinical decision making and in serving as a source of clinical information and case reports as well.
The main journal, JCSM, has, at the time of this writing, received 294 submissions in 2019 alone. Last year at this time, we had received 209. We are working hard to provide a timely peer review, which is not always easy, as it is difficult at times to find appropriate reviewers. Articles that are available for the longest time are-not surprisingly-those that have been cited the most ( Table 3) . Our editorials remain popular (Table 4) , and we invite our readers to submit their work or to suggest topics for 'facts and numbers' editorials that are relevant to our readers. Finally, we would like to draw your attention to the upcoming Cachexia Conference, to be held between December 6 and 8, 2019, in Berlin, Germany. The conference became an annual meeting, and it is a source of stimulating ideas and exchange between clinicians and researchers in the field of cachexia and wasting. More information can be found at the following link: http://society-scwd.org. 
